0001179110-14-014724.txt : 20141001 0001179110-14-014724.hdr.sgml : 20141001 20141001170441 ACCESSION NUMBER: 0001179110-14-014724 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140929 FILED AS OF DATE: 20141001 DATE AS OF CHANGE: 20141001 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MERRIMACK PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001274792 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: SUITE B7201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-441-1000 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: SUITE B7201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sullivan William A. CENTRAL INDEX KEY: 0001531562 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35409 FILM NUMBER: 141133766 MAIL ADDRESS: STREET 1: MERRIMACK PHARMACEUTICALS, INC. STREET 2: ONE KENDALL SQUARE, SUITE B7201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2014-09-29 0 0001274792 MERRIMACK PHARMACEUTICALS INC MACK 0001531562 Sullivan William A. C/O MERRIMACK PHARMACEUTICALS, INC. ONE KENDALL SQUARE, SUITE B7201 CAMBRIDGE MA 02139 0 1 0 0 CFO and Treasurer Common Stock 2014-09-29 4 M 0 64404 2.12 A 75404 D Common Stock 2014-09-29 4 S 0 64404 8.40 D 11000 D Common Stock 2014-09-30 4 M 0 40878 2.69 A 51878 D Common Stock 2014-09-30 4 S 0 40878 8.94 D 11000 D Stock Option (right to buy) 2.12 2014-09-29 4 M 0 64404 0 D 2017-12-04 Common Stock 64404 10596 D Stock Option (right to buy) 2.69 2014-09-30 4 M 0 40878 0 D 2020-12-21 Common Stock 40878 109122 D This transaction was effected pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.40 to $8.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.90 to $8.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. This option is fully vested. /s/ Jeffrey A. Munsie, attorney-in-fact 2014-10-01